ETFs Holding EPZM »    EPZM Historical Stock Prices »
EPZM News Video: Mon, Oct 8, 2018, 10:31 AM — Monday 10/8 Insider Buying Report: EPZM, IIPR

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Epizyme is a clinical stage biopharmaceutical company that is focused on the treatment of cancer and other diseases through discovering, developing, and commercializing epigenetic medicines. Co. is developing its primary product candidate, tazemetostat, an oral selective inhibitor of the EZH2 histone methyltransferase in a range of cancer types and settings, and developing the primary development candidate in its G9a program, EZM8266, for the treatment of sickle cell disease. Co. also has a pipeline of drug discovery programs that target its other chromatin modifying proteins. These programs are directed to specific cancers, including both hematological malignancies and solid tumors. Self directed investors in Epizyme Inc. will be interested in keeping up with all Epizyme Inc. news they can find, both EPZM news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on EPZM. At RediNews, we simplify this task by presenting both EPZM news releases originating from Epizyme Inc. itself, and EPZM news from a variety of media outlets. Visitors can browse this news online and through our EPZM RSS news feed.


EPZM News — Articles, Videos, & Press Releases

Surprising Analyst 12-Month Target For TUSA
Friday, May 10, 2019, 8:20 AM — ETF Channel
Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates
Monday, May 6, 2019, 5:45 AM — Zacks
Analysts Forecast 10% Upside For VBK
Friday, April 5, 2019, 8:12 AM — ETF Channel
Epizyme Stock Sees Short Interest Drop 13.8%
Wednesday, March 27, 2019, 11:46 AM — Market News Video
First Week of EPZM November 15th Options Trading
Wednesday, March 20, 2019, 10:45 AM — Stock Options Channel
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4
Wednesday, February 27, 2019, 9:14 AM — Zacks
5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
Thursday, February 14, 2019, 11:58 AM — Zacks
Analysts See 61% Gains Ahead For XBI
Wednesday, January 30, 2019, 7:42 AM — ETF Channel
First Week of August 16th Options Trading For Epizyme (EPZM)
Friday, January 4, 2019, 10:45 AM — Stock Options Channel
The Math Shows PBSM Can Go To $33
Thursday, December 20, 2018, 7:58 AM — ETF Channel
Epizyme is Now Oversold (EPZM)
Thursday, December 13, 2018, 12:01 PM — Dividend Channel
Analysts Anticipate IBB Will Reach $145
Monday, November 19, 2018, 7:39 AM — ETF Channel
Oversold Conditions For Epizyme (EPZM)
Monday, October 22, 2018, 11:52 AM — Dividend Channel
XBI's Holdings Could Mean 57% Gain Potential
Thursday, October 18, 2018, 7:46 AM — ETF Channel
Interesting EPZM Put And Call Options For May 2019
Wednesday, October 3, 2018, 10:37 AM — Stock Options Channel
Commit To Buy Epizyme At $7.50, Earn 8.3% Annualized Using Options
Monday, September 24, 2018, 11:51 AM — Stock Options Channel
How The Pieces Add Up: XBI Headed For $138
Monday, September 17, 2018, 7:50 AM — ETF Channel
PBSM's Holdings Could Mean 10% Gain Potential
Tuesday, August 7, 2018, 8:50 AM — ETF Channel
Epizyme is Now Oversold
Thursday, August 2, 2018, 11:56 AM — Dividend Channel
Epizyme Becomes Oversold (EPZM)
Tuesday, July 3, 2018, 12:01 PM — Dividend Channel
Implied FAD Analyst Target Price: $79
Thursday, June 28, 2018, 8:31 AM — ETF Channel
First Week of EPZM February 2019 Options Trading
Thursday, June 21, 2018, 10:47 AM — Stock Options Channel
First Week of July 20th Options Trading For Epizyme (EPZM)
Tuesday, June 12, 2018, 11:27 AM — Stock Options Channel
EPZM is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

KIN News

RediNews asks: are you the content manager in charge of web publishing content for web site stock quote, stock chart, forex, pages with historical price data for the markets, or other types of custom financial content like pink sheets symbols, option symbols, and stock portfolio pages? Then you should add RediNews RSS feeds to your arsenal of free financial website content and financial tools, adding another element of dynamic stock content to your pages with a constantly updating menu of recent news headlines for individual stocks and market sectors. So give our financial news feed a try by clicking the RSS icon for any news page (which will look like this): .

EPZM News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.